Linu Mohan - Prevalence <strong>of</strong> Metabolic Syndrome in Psychiatric Outpatients in a Tertiary Care Hospital, Kerala.Table V- Comparison <strong>of</strong> Baseline and Review Values <strong>of</strong> Various Paramerters with their Statistical Significance.Variables Sample (N) Mean SD % Mean SD <strong>of</strong> Paired df p-valuedifference difference mean t-testdifferenceBMI-I 25 26.2610 3.88526 3.14% -8.2616 .60624 -6.814 24 .001BMI-II 25 27.0872 3.72915WAIST -I(in cms) 25 92.72 7.547 3.88% -3.600 2.179 -8.259 24 .001WAIST-II (in cms) 25 96.32 7.936SBP-I 25 126.40 9.522 2.84% -3.600 9.522 -1.890 24 .071SBP-II 25 130.00 2.887DBP-I 25 83.80 6.964 6.92% -5.800 7.455 -3.890 24 .001DBP-II 25 89.60 3.202TG-I 251 35.561 4.480 3.18% -4.320 5.460 -3.956 24 .001TG-II 25 139.88 16.435HDL-I 25 60.88 10.822 -8.08% 4.920 6.812 3.611 24 .001HDL-II 25 55.96 13.043FBS-I 25 97.80 13.586 10.18% -9.960 7.202- 6.914 24 .001FBS-II 25 107.76 16.984I-baseline,15serial indicators for risk during antipsychotic treatment.Treatment <strong>of</strong> the metabolic syndrome focuses on lifestylemodifications which include dietary changes and exercise.The pr<strong>of</strong>essionals need to be aware <strong>of</strong> the existence <strong>of</strong> themetabolic syndrome, be vigilant to its development and takeprompt steps to rectify it.REFERENCESII-review1. Mattoo SK, Singh SM. Metabolic syndrome and psychiatricdisorders. <strong>Indian</strong> J Med 2008; 237-45.2. The IDF consensus worldwide definition <strong>of</strong> the metabolicsyndrome, 2006, http://www.idf.org/webdata/docs/MetS defupdate2006.pdf (Ref type: electronic citation).3. Izet Aganovic, Tina Dusek. Pathophysiology <strong>of</strong> metabolicsyndrome. New trends in classification, monitoring andmanagement <strong>of</strong> metabolic syndrome 2006; 1:1-3.4. European <strong>Journal</strong> <strong>of</strong> Cardiovascular Prevention andRehabilitation 2003; 10:S1-S78.5. Ford ES, Giles WH, Dietz WH. Prevalence <strong>of</strong> the metabolicsyndrome among U.S. adults: findings from the Third NationalHealth and Nutrition Examination Survey. JAMA 2002; 287:356-9.6. Bermudes RA, Keck PE, Welge JA. The prevalence <strong>of</strong> themetabolic syndrome in psychiatric inpatients with primarypsychotic and mood disorders. Psychosomatics 2006; 47:491-7.7. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence <strong>of</strong>metabolic syndrome using WHO, ATPIII and IDF definitions inAsian <strong>Indian</strong>s: the Chennai urban rural epidemiology study(CURES-34). Diabetes Metab Res Rev 2007; 23:127-34.8. McElroy Susan L, Mark Frye A, Gerhard Hellemann, LoriAltshuler, Gabriele Leverich S. Prevalence and correlates <strong>of</strong>eating disorders in 875 patients with bipolar disorder. Jour <strong>of</strong>Affect Disord 2011; 128:191-8.9. Hamid A, Saheera AH, Baharudin A, Sidi H. Metabolic syndromein psychiatric patients with primary psychotic and mooddisorders. ASEAN Jour <strong>of</strong> Psych 2009; 2(10);1-8.10. Kasanin J. The blood sugar curve in mental disease. Arch NeurolPsychiatry 1926; 16:414-9.11. Alexander P J, Radhakrishnan K, Milan D, Stephen C B.Prevalence <strong>of</strong> metabolic syndrome among Australians withsevere mental illness. MJA 2009; 190:176-9.12. Ryan MCM, Flanagan S, Kinsella U. The effects <strong>of</strong> atypicalantipsychotics on visceral fat distribution in first episode, drugnaivepatients with schizophrenia. Life Sci 2004; 74:1999–2008.13. Siever LJ, Davis KL. Overview towards a dysregulationhypothesis <strong>of</strong> depression. Am J Psychiatry 1985; 142:1017-31.14. Keck PE Jr, Buse JB, Dagogo-Jack S. Managing metabolicconcerns in patients with severe mental illness: a special report.Postgrad Med, McGraw-Hill, Minneapolis, MN, 2003;1-92.15. Daniel Casey E. Metabolic issues and cardiovascular disease inpatients with psychiatric disorders. The American <strong>Journal</strong> <strong>of</strong>Medicine 2005; 118:15-22.<strong>Indian</strong> <strong>Journal</strong> <strong>of</strong> <strong>Pharmacy</strong> <strong>Practice</strong> Volume 5 Issue 3 <strong>Jul</strong> - <strong>Sep</strong>, <strong>2012</strong> 61
<strong>Indian</strong> <strong>Journal</strong> <strong>of</strong> <strong>Pharmacy</strong> <strong>Practice</strong>Association <strong>of</strong> Pharmaceutical Teachers <strong>of</strong> IndiaAssessment <strong>of</strong> Drug Prescribing Patterns in Dermatology Outpatient Department ina Tertiary Care Hospital, Malabar, KeralaMohamed Saleem T.K*, Dilip. C and Nishad V.KAl Shifa College <strong>of</strong> <strong>Pharmacy</strong>, Kizhattur, Perinthalmanna, Kerala.Pin-679325A B S T R A C TSubmitted: 04/07/<strong>2012</strong>Accepted: 27/07/<strong>2012</strong>Skin diseases in developing countries have a serious impact on people's quality <strong>of</strong> life. Occasionally skin diseases can be a manifestation <strong>of</strong>systemic diseases. A prospective study was carried out over six months (August 2010-January 2011) in the Dermatology outpatient department <strong>of</strong>tertiary care referral hospital in Malabar region <strong>of</strong> Kerala. A total <strong>of</strong> 500 cases were analyzed in which the total number <strong>of</strong> drugs was found to be1230. The most commonly prescribed systemic agents were antihistamine (294) followed by antibiotics (181) & antifungal agents (49). The mostcommonly prescribed topical agents were topical steroids & its combination (236) followed by topical antifungal agents (124). This study revealsthat generic prescription is very low and suggests that effort must be made to encourage prescribers for generic prescribing which may have amultitude <strong>of</strong> benefits including cost effectiveness. Having a steroid and antibiotic prescribing policy will go a long way to minimizing inappropriateprescriptions and also standard treatment guidelines for the treatment <strong>of</strong> common disease should be formulated.Keywords: Skin diseases, dermatology,INTRODUCTIONSkin diseases in developing countries have a serious impacton people's quality <strong>of</strong> life, it is more so in India where climate,socio-economic status, religions and customs are widelyvaried in different parts <strong>of</strong> the country. Occasionally skindiseases can be a manifestation <strong>of</strong> systemic diseases.Moreover, the skin is an important target organ for HIV1, 2infection , that could be prevented or controlled by, amongother measures, appropriate use <strong>of</strong> drugs.Rational use <strong>of</strong> drugs is defined by World HealthOrganization (WHO) as “patients receive medicinesappropriate to their clinical needs, in doses that meet theirown individual requirements for an adequate period <strong>of</strong> time,3at the lowest cost to them and their community” . WHOhighlights two concomitant problems regarding the drugsituation in the developing world: one out <strong>of</strong> three peopleliving in the developing world are in need <strong>of</strong> essential drugsalthough there are concurrent higher rates <strong>of</strong> inappropriate4drug-use and drug resistance . WHO has estimated that atleast one-third <strong>of</strong> the world's population lacks access toessential drugs. In poorer areas <strong>of</strong> Asia and Africa this figuremay be as high as one-half. Millions <strong>of</strong> children and adults dieeach year from diseases that could have been prevented ortreated with cost-effective and inexpensive essential drugs.Address for Correspondence:Mohamed Saleem T.K, Assistant Pr<strong>of</strong>essor, Al Shifa College <strong>of</strong> <strong>Pharmacy</strong>,Kizhattur, Perinthalmanna.E-mail: mohamedsaleemtk@gmail.comThe WHO also estimates that 50 percent <strong>of</strong> all medicines are5 .inappropriately prescribed, dispensed, or sold According tothe 1985 WHO Conference <strong>of</strong> Experts on drug-use,appropriate or rational use <strong>of</strong> medicines is only when drugsare prescribed when clinically indicated, and at correctdosages for the right duration and at the lowest cost both to thepatient and their community. Inappropriate drug use hasdirect and indirect cost to the health system and individuals. Itis estimated that third world countries spend 30-40% <strong>of</strong> theirtotal health budget on drugs some <strong>of</strong> which are useless andexpensive and doubles their expenditure on drugs every 4years while GNP (Gross National Product) doubles every 16years. According to planning commission paper <strong>of</strong> 2009,health care expenses were responsible over half <strong>of</strong> all casesdecline into poverty. It was estimated in 2004-05, anadditional 39 million people were pushed into poverty due toout <strong>of</strong> pocket payment. National sample survey <strong>of</strong>fice(NSSO) data for the same year had shown that <strong>of</strong> the totalmedical expenditure percapita, medicines alone accountedfor 74% <strong>of</strong> the expenses in the rural and 67% in urban areas. Itis more in non-government sector. It indicates huge impact <strong>of</strong>rising price on health expenditure. This expenditure can beminimized by prescribing drugs by generic name and6selection <strong>of</strong> drugs from essential medicine list Therefore,periodic evaluation <strong>of</strong> drug utilization patterns need to bedone to enable suitable modifications in prescription <strong>of</strong> drugsto increase the therapeutic benefit and decrease the adverseeffects. People <strong>of</strong>ten have very rational reasons for usingmedicines irrationally. Causes <strong>of</strong> irrational use include lack <strong>of</strong>knowledge, skills or independent information, unrestricted<strong>Indian</strong> <strong>Journal</strong> <strong>of</strong> <strong>Pharmacy</strong> <strong>Practice</strong> Volume 5 Issue 3 <strong>Jul</strong> - <strong>Sep</strong>, <strong>2012</strong> 62